About Jonathan Tobin
Jonathan joined Imperial Innovations in 2011 and specialises in therapeutics and diagnostics investments. He is a board director with diagnostics companies Abingdon Health and Molecular Vision, and a board observer with Cell Medica. Prior to joining Imperial Innovations he worked at MRC Technology, sourcing and evaluating new opportunities for small molecule and antibody drug discovery worldwide. He has a PhD in molecular medicine from UCL, and undertook post-doctoral research at the Cancer Research UK LRI. Jonathan has a First Class degree in Biology from Oxford University and an MBA with Distinction from Imperial College.